MedTrace Logo

Use of (-)-Epicatechin in the Treatment of Becker Muscular Dystrophy (Pilot Study)

NCT01856868 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2021-12-22

Study results available
· View outcomes & findings →

Summary

(-)-Epicatechin will be evaluated for the treatment of progressive muscle loss and impaired skeletal muscle function in Becker Muscular Dystrophy (BMD) patients.

Conditions

  • Becker Muscular Dystrophy

Interventions

DRUG

(-)-epicatechin

purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.

Sponsors & Collaborators

  • Cardero Therapeutics, Inc.

    collaborator INDUSTRY

  • Craig McDonald, MD

    lead OTHER

Principal Investigators

  • Craig M McDonald, MD · University of California, Davis

  • Erik K Henricson, MPH · University of California, Davis

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-05-31
Primary Completion
2018-09-30
Completion
2018-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01856868 on ClinicalTrials.gov